There is no doubt that Teva- Pharmaceutical Industries Ltd. ADR (TEVA) ticks all the boxes.

With 18.44 million shares changed hands, the volume of the stock remained heavier than its average volume of 9.99 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $16.99 whereas the lowest price it dropped to was $16.29. The 52-week range on TEVA shows that it touched its highest point at $16.57 and its lowest point at $7.09 during that stretch. It currently has a 1-year price target of $18.00. Beta for the stock currently stands at 0.89.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TEVA was up-trending over the past week, with a rise of 20.06%, but this was up by 26.92% over a month. Three-month performance surged to 30.75% while six-month performance rose 92.47%. The stock gained 105.60% in the past year, while it has gained 61.69% so far this year. A look at the trailing 12-month EPS for TEVA yields -0.42 with Next year EPS estimates of 2.70. For the next quarter, that number is 0.60. This implies an EPS growth rate of -4.95% for this year and 11.13% for next year. EPS is expected to grow by 1.60% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 26.63%.

Float and Shares Shorts:

At present, 1.12 billion TEVA shares are outstanding with a float of 1.12 billion shares on hand for trading. On 2024-04-30, short shares totaled 11.66 million, which was 108.0 higher than short shares on 1711584000. In addition to Mr. Richard D. Francis as the firm’s President, CEO & Director, Mr. Eliyahu Sharon Kalif serves as its Executive VP & CFO.

Institutional Ownership:

Through their ownership of 0.49982 of TEVA’s outstanding shares, institutional investors have minority control over the company.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, TEVA reported revenue of $3819000000.0 and operating income of $642000000.0. The EBITDA in the recently reported quarter was $932000000.0 and diluted EPS was -$0.12.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TEVA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.